Breaks Categories: Stock Spotlights

TuesdayMar 28, 2017 10:41 am

NetworkNewsBreaks – RXi Pharmaceuticals Corp. (NASDAQ: RXII) Strengthens RXI-109 Intellectual Property with New Patent in Japan; Shares Rise

RXi Pharmaceuticals (NASDAQ: RXII) shares are up more than 38% this morning after the company said it has been granted a patent by the Japan Patent Office for the composition of matter of sd-rxRNAs targeting connective tissue growth factor for the treatment or prevention of fibrotic disorders. Fibrotic disorders covered include, but are not limited to, skin fibrosis and proliferative retinopathy. This patent includes RXI-109, the company’s lead clinical candidate, which is currently being evaluated in phase 2 clinical trials. The patent will expire in 2031. "The granting of this patent in Japan further strengthens RXi's intellectual property estate for…

Continue Reading

ThursdayMar 23, 2017 12:55 pm

NetworkNewsBreaks – ImmuDyne, Inc. (IMMD) Shares Surge on Completed Formulation of Shapiro MD Product Line

ImmuDyne (OTCQB: IMMD) shares are 21.5% higher mid-day following early news that all formulation work has been completed on the Shapiro MD product line. The first product run will transpire in the next 2-3 weeks, and a national product launch is anticipated no later than April 15, 2017. The all natural and patented hair loss product line will include shampoo, conditioner, and a once-daily leave-in foam product. "We’re very excited for the product launch and are very optimistic that the 10 years we invested in research and development to create Shapiro MD will benefit people around the world that want…

Continue Reading

ThursdayMar 23, 2017 12:53 pm

NetworkNewsBreaks – Egalet Corp. (NASDAQ: EGLT) Receives New U.S. and International Patents for Guardian™ Technology

Shares of Egalet (NASDAQ: EGLT) are up 4.5% mid-day on word the company has received new U.S. and international patents for its proprietary Guardian™ Technology, bringing the number to 18 U.S. patents and 95 international patents. The United States Patent and Trademark Office (USPTO) has issued a patent covering the company’s ARYMO™ ER extended-release tablets for oral use only. It is the second U.S. patent covering ARYMO ER and offers protection through 2033 and is listed in the Orange Book. A European patent has also been issued to Egalet and offers protection of products developed using Guardian Technology. Additionally, an…

Continue Reading

ThursdayMar 23, 2017 12:50 pm

NetworkNewsBreaks – Sphere 3D Corp.’s (NASDAQ: ANY) HVE Solution Selected by The Beck Group for VDI; Shares Higher

Shares of Sphere 3D (NASDAQ: ANY) are trading higher after the company this morning said that The Beck Group has successfully employed an HVE solution for its Virtual Desktop Infrastructure (VDI), including VDI for GPU intensive workloads. The inclusion of the HVE 3DGFX appliances for running computer aided design (CAD) applications provides a powerful server-based computing environment for The Beck Group. The CAD data processed by the server provides a faster, more effective utilization of resources and enables staff to access their workloads from any device, anywhere. “We are delighted to have the opportunity to provide them with a high…

Continue Reading

WednesdayMar 22, 2017 12:35 pm

NetworkNewsBreaks – Sequential Brands Group, Inc. (NASDAQ: SQBG) Names Replacement for Departing CEO; Shares Lower

Shares of Sequential Brands Group (NASDAQ: SQBG) are down 10% after the company this morning named Karen Murray as chief executive officer to replace Yehuda Shmidman, who is stepping down from his position at the company and as a member of the board of directors. Murray has also been appointed to serve as a director of the company. “Karen Murray has outstanding leadership skills and industry experience and she has demonstrated her ability to activate and grow successful brands. We are excited to have an executive of Karen’s caliber join and lead our team at Sequential to grow with us. …

Continue Reading

WednesdayMar 22, 2017 12:27 pm

NetworkNewsBreaks – MGX Minerals (MGXMF) Takes Aim at Growing Lithium Market With Cheaper Extraction Process

MGX Minerals (OTC: MGXMF) holds the largest lithium portfolio in Canada and has its sights set on the booming global lithium market, projected to reach $5.87 billion by 2020. “Positive developments have made the company’s lithium operations a special point of interest. An important factor is the company’s engineering partner Purlucid Treatment Solutions, which has developed technologies representing a major step in the process of extracting lithium from petroleum brine water (petrolithium). MGX already holds the largest lithium portfolio in Canada, with its Sturgeon Lake property in Alberta and other lithium assets, and the company is the sole proprietary technology…

Continue Reading

WednesdayMar 22, 2017 12:24 pm

NetworkNewsBreaks – National Waste Management Holdings, Inc. (NWMH) Maintains Steady Focus on Expansion

National Waste Management Holdings (OTC: NWMH) has set what some would consider a lofty objective of four acquisitions per year. With an impressive track record of doing so, however, the management team at National Waste has demonstrated its ability to meet this goal and diversify its revenue streams. “These days, National Waste continues to press forward with an aggressive business model that calls for one acquisition per quarter by seeking out acquisitive opportunities in Upstate New York and Florida. To name a few, the company acquired both Sivart Services, a roll-off and compactor company in Worchester, NY, and Northeast Data…

Continue Reading

WednesdayMar 22, 2017 12:22 pm

NetworkNewsBreaks – Moleculin Biotech, Inc. (NASDAQ: MBRX) Shares Spike on Orphan Drug Designation for Annamycin

Moleculin Biotech (NASDAQ: MBRX) shares are 31% higher mid-morning after the company said it has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for Annamycin for the treatment of acute myeloid leukemia (AML). This designation will provide the company several benefits, such as tax credits for qualified clinical trials costs, exemptions from certain FDA application fees, and seven years of market exclusivity upon regulatory product approval. "We are pleased to report this key milestone and the FDA's decision to grant Annamycin orphan drug designation. We look forward to announcing additional milestones in regard to our clinical…

Continue Reading

WednesdayMar 22, 2017 10:44 am

NetworkNewsBreaks – UniPixel, Inc. (NASDAQ: UNXL) Defies Market Slump; Shares Rise on Multi-Year Deal with Major PC Maker

Shares of UniPixel (NASDAQ: UNXL) are up more than 16% this morning after the company said it has entered into a long-term agreement with a major U.S.-based PC maker to supply XTouch touch screen sensors for multiple years. Per the agreement, the PC maker will supply rolling forecasts to UniPixel and will use its best commercial efforts to make the purchases outlined in the rolling forecasts. The company will reserve manufacturing capacity for the PC maker based off of the rolling forecasts. The agreement also permits the PC maker to request limited, exclusive early access to certain technology development advancements,…

Continue Reading

TuesdayMar 21, 2017 1:10 pm

NetworkNewsBreaks – Cellectar Biosciences, Inc. (NASDAQ: CLRB) Obtains Patent for Use of CLR 124 in PET Imaging

Cellectar Biosciences (NASDAQ: CLRB) this morning said the United States Patent and Trademark Office has granted a method of use patent for CLR 124, the cancer imaging agent that utilizes the company’s proprietary phospholipid drug conjugate (PDC) delivery platform. The newly issued patent, titled “Phospholipid Ether Analogs as Agents for Detecting and Locating Cancer and Methods Thereof,” provides intellectual property protection through March 2, 2025. The patent outlines the use of CLR 124 in PET imaging to detect radiation-insensitive or chemotherapy-insensitive cancers and cancer metastases. Additionally, the patent provides coverage for the use of CLR 124 in identifying the location…

Continue Reading